November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Yan Leyfman: Injectable Semaglutide Shows Significant Reductions in Weight and Pain for Osteoarthritis Patients
Nov 7, 2024, 13:09

Yan Leyfman: Injectable Semaglutide Shows Significant Reductions in Weight and Pain for Osteoarthritis Patients

Yan Leyfman, Co-founder and Executive Director of MedNews Week shared a post on LinkedIn, highlighting a study by Henning Bliddal et al. adding his own thoughts:

“Study in 407 patients with mean age was 56, mean BMI 40.3, and mean WOMAC pain score 70.9 who had obesity & knee osteoarthritis with moderate-to-severe pain, treatment with once-weekly injectable semaglutide resulted in significantly greater reductions in body weight and pain related to knee osteoarthritis.”

Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis

Authors: Henning Bliddal, M.D., Harold Bays, M.D., Sébastien Czernichow, M.D., Ph.D., Joanna Uddén Hemmingsson, M.D., Ph.D., Jøran Hjelmesæth, M.D., Ph.D., Thomas Hoffmann Morville, M.D., Ph.D., Anna Koroleva, M.D., Jesper Skov Neergaard, Ph.D., Patricia Vélez Sánchez, M.D., Sean Wharton, M.D., Alicja Wizert, Ph.D., and Lars E. Kristensen, M.D., Ph.D., for the STEP 9 Study Group

Yan Leyfman: Injectable Semaglutide Shows Significant Reductions in Weight and Pain for Osteoarthritis Patients

Yan Leyfman MD, is the Co-founder and executive director of MedNews Week. He is also the medical correspondent at OncLive. He is also the Executive Committee Member at Music Beats Cancer. He is a Clinical Researcher at Icahn School of Medicine at Mount Sinai. His research interests include oncology, Immunooncology, Cellular Therapy, and Immunotherapy.”